DE69512219D1 - Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen - Google Patents

Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen

Info

Publication number
DE69512219D1
DE69512219D1 DE69512219T DE69512219T DE69512219D1 DE 69512219 D1 DE69512219 D1 DE 69512219D1 DE 69512219 T DE69512219 T DE 69512219T DE 69512219 T DE69512219 T DE 69512219T DE 69512219 D1 DE69512219 D1 DE 69512219D1
Authority
DE
Germany
Prior art keywords
targeted
egs
rnaase
rna
stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69512219T
Other languages
English (en)
Other versions
DE69512219T2 (de
Inventor
Yan Yuan
Cecilia Guerrier-Takada
Sidney Altman
Fenyong Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/207,547 external-priority patent/US5624824A/en
Application filed by Yale University filed Critical Yale University
Publication of DE69512219D1 publication Critical patent/DE69512219D1/de
Application granted granted Critical
Publication of DE69512219T2 publication Critical patent/DE69512219T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69512219T 1994-03-07 1995-03-07 Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen Expired - Fee Related DE69512219T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/207,547 US5624824A (en) 1989-03-24 1994-03-07 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US08/215,082 US5728521A (en) 1989-03-24 1994-03-18 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
PCT/US1995/002816 WO1995024489A1 (en) 1994-03-07 1995-03-07 Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences

Publications (2)

Publication Number Publication Date
DE69512219D1 true DE69512219D1 (de) 1999-10-21
DE69512219T2 DE69512219T2 (de) 2000-01-20

Family

ID=26902350

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512219T Expired - Fee Related DE69512219T2 (de) 1994-03-07 1995-03-07 Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen

Country Status (8)

Country Link
US (2) US5869248A (de)
EP (1) EP0748383B1 (de)
JP (1) JPH10508181A (de)
AT (1) ATE184649T1 (de)
AU (1) AU696138B2 (de)
CA (1) CA2185117A1 (de)
DE (1) DE69512219T2 (de)
WO (1) WO1995024489A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
US5976874A (en) * 1996-08-16 1999-11-02 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
US8293224B2 (en) * 2000-02-07 2012-10-23 Trustees Of Dartmouth College Attenuated uracil auxotroph of an apicomplexan and use thereof
JP2003534789A (ja) * 2000-05-31 2003-11-25 イスティトゥート ディ バイオロジア チェルラーレ，シーエヌアール Ｒｎａ切断方法
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
CN1856504B (zh) 2002-02-06 2010-12-29 史戴西思技术有限公司 抗梗塞分子
WO2003093452A2 (en) * 2002-02-26 2003-11-13 University Of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
US7858367B2 (en) * 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
US20030215872A1 (en) * 2002-05-20 2003-11-20 Clark-Mxr, Inc. Screening apparatus and method for making
US20030215815A1 (en) * 2002-05-20 2003-11-20 Clark William G. Screening method
US20050287648A1 (en) 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
CN1780920B (zh) * 2003-05-12 2012-03-28 波多玛克制药有限公司 基因表达抑制剂
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
JP2007535579A (ja) * 2004-04-29 2007-12-06 イェール ユニバーシティ 炎症性疾患およびウイルス関連性呼吸器疾患を処置するためのヌクレアーゼ耐性外部ガイド配列
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
JP4911915B2 (ja) 2005-05-09 2012-04-04 トヨタ自動車株式会社 標的物の分解方法及び分解装置
CA2625349A1 (en) * 2005-10-06 2007-04-19 Emthrax, Llc Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1934331A4 (de) 2005-10-14 2009-01-21 Musc Found For Res Dev Pax2 als ziel für die induktion von defb1-vermittelter tumorimmunität und krebstherapie
EP1981548A4 (de) * 2006-01-20 2010-03-24 Univ North Carolina Verstärkte produktion von infektiösen parvovirus-vektoren in insektenzellen
EP1998792B1 (de) 2006-03-01 2015-02-18 The University of Utah Research Foundation Verfahren und zusammensetzungen in verbindung mit der synthese zyklischer peptide
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
WO2008036406A2 (en) 2006-09-21 2008-03-27 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
CA2672297A1 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
US9493817B2 (en) 2007-03-05 2016-11-15 Genesis Research Institute, Inc. Decomposition method and decomposition apparatus for nucleic acid polymer
US20100239596A1 (en) * 2007-08-22 2010-09-23 University Of Southern California Grp78 and tumor angiogenesis
CA2704729C (en) * 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2195340A4 (de) 2007-08-28 2011-05-11 Uab Research Foundation Synthetische apolipoprotein e-imitierende polypeptide und verwendungsverfahren
EP2268664B1 (de) * 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Doc1-zusammensetzungen und verfahren zur behandlung von krebs
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
US9822364B2 (en) 2008-03-11 2017-11-21 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
US9241898B2 (en) 2008-03-11 2016-01-26 Yale University Compositions and methods for controlled delivery of inhibitory ribonucleic acids
JP2011517410A (ja) * 2008-04-08 2011-06-09 アミリス バイオテクノロジーズ， インコーポレイテッド 異種配列の発現
EP2853897A1 (de) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensorische Rezeptoren für chronische Müdigkeit und Schmerzen und Verwendungen davon
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2010074924A1 (en) 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
WO2010093784A2 (en) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20120077753A1 (en) 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US20110274745A1 (en) 2009-11-10 2011-11-10 Lipella Pharmaceuticals Inc. Instillation of liposomal formulation of sirna and antisense oligonucleotides
US8889615B2 (en) 2009-12-31 2014-11-18 New York University Methods for promoting epithelialization and healing of chronic wounds
WO2011088081A1 (en) 2010-01-12 2011-07-21 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
JP2014505239A (ja) 2010-12-14 2014-02-27 モアハウス スクール オブ メディスン 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
EP4234571A3 (de) 2011-02-10 2023-09-27 The University of North Carolina at Chapel Hill Virale vektoren mit modifizierten transduktionsprofilen sowie verfahren zu ihrer herstellung und verwendung
CA2836898A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
CN102568437B (zh) 2012-01-20 2014-07-30 华为终端有限公司 图像显示方法及设备
AU2013323270B2 (en) 2012-09-28 2017-09-28 The University Of North Carolina At Chapel Hill AAV vectors targeted to oligodendrocytes
EP2970966A4 (de) 2013-03-15 2016-10-26 Univ North Carolina Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
CN105163764B (zh) 2013-03-15 2019-11-12 北卡罗来纳-查佩尔山大学 双重聚糖结合aav载体的方法和组合物
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
IL251951B (en) 2014-10-27 2022-07-01 Univ Central Florida Res Found Inc Methods and compositions for natural killer cells
CN114480440A (zh) 2014-11-21 2022-05-13 北卡罗来纳-查佩尔山大学 靶向中枢神经系统的aav载体
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
WO2016127057A1 (en) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
IL292830B2 (en) 2015-09-28 2023-06-01 Univ Florida Methods and compositions for stealth virus antibody vectors
WO2017190031A1 (en) 2016-04-28 2017-11-02 Indiana University Research And Technology Corporation Methods and compositions for resolving components of a virus preparation
KR20190037273A (ko) 2016-08-03 2019-04-05 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Tlr9 표적 치료제
US11597708B2 (en) 2016-09-16 2023-03-07 Hsf Pharmaceuticals Sa Inhibitors of heat shock factors and uses thereof
AU2018234695A1 (en) 2017-03-15 2019-09-12 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
US11668719B2 (en) 2017-09-20 2023-06-06 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
EP3738137A1 (de) 2018-01-12 2020-11-18 The Trustees of Indiana University Konstruktion einer elektrostatischen linearen ionenfalle für massenspektrometrie mit ladungsdetektion
CN112533644A (zh) 2018-04-03 2021-03-19 斯特里迪比奥公司 靶向眼组织的病毒载体
BR112020020195A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
WO2019236142A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
AU2019281714B2 (en) 2018-06-04 2024-05-02 The Trustees Of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
EP3803952A1 (de) 2018-06-04 2021-04-14 The Trustees of Indiana University Vorrichtung und verfahren zum einfangen von ionen in einer elektrostatischen linearen ionenfalle
US20210269828A1 (en) 2018-06-22 2021-09-02 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
KR20210100086A (ko) 2018-10-04 2021-08-13 유니버시티 오브 로체스터 혈장 오스몰농도 조작에 의한 글림프 전달의 개선
CA3118267A1 (en) 2018-11-20 2020-05-28 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
AU2019392058A1 (en) 2018-12-03 2021-05-27 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
US11942317B2 (en) 2019-04-23 2024-03-26 The Trustees Of Indiana University Identification of sample subspecies based on particle mass and charge over a range of sample temperatures
EP4169535A1 (de) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für dualen glycanbindenden aav2,5-vektor
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療ｃ型尼曼—匹克病之腺相關病毒載體
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
EP4010356B1 (de) 2020-10-28 2024-09-04 The University of North Carolina at Chapel Hill Verfahren und zusammensetzungen für dualen glycanbindenden aav2.5-vektor
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
US20240189447A1 (en) 2021-04-16 2024-06-13 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
WO2023122720A1 (en) 2021-12-23 2023-06-29 University Of Rochester Compositions and methods for delivery of agents to inner ear
WO2023122719A2 (en) 2021-12-23 2023-06-29 University Of Rochester Csf transport pathway for delivery of agents to inner ear
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0228458B2 (de) * 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
GB2213684A (en) * 1987-12-11 1989-08-16 Philips Electronic Associated Data demodulator baud clock phase locking
AU632993B2 (en) * 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
JP2917998B2 (ja) * 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
DE68929361T2 (de) * 1988-04-27 2002-06-20 Isis Pharmaceuticals, Inc. Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
EP0380656A1 (de) * 1988-08-16 1990-08-08 Yale University Defiziente hepadna-viren, produktive zellinie für impfstoffe sowie behandlung von erkrankungen und störungen der leber
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5624824A (en) * 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
JPH05506993A (ja) * 1990-04-20 1993-10-14 ザ・ジェネラル・ホスピタル・コーポレーション ウイルスの複製を防止する方法
WO1991017093A1 (en) * 1990-05-07 1991-11-14 Anchor Hocking Corporation A composite closure, disk and package
DE4216134A1 (de) * 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
DE69303712T2 (de) * 1992-04-28 1997-02-20 Univ Yale Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz
EP1195442A3 (de) * 1992-12-04 2002-07-31 Innovir Laboratories, Inc. Signalverstärkung mittels Ribozyme im Diagnoseverfahren
JPH08507203A (ja) * 1992-12-04 1996-08-06 イノーバー ラボラトリーズ，インコーポレイテッド 調節可能な核酸治療およびそれらの使用方法
IL108206A0 (en) * 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
US6012375A (en) * 1993-07-06 2000-01-11 Eckstein; Donald B. Aircraft infrared guided defense missile system
AU706417B2 (en) * 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
AU4961996A (en) * 1994-12-14 1996-07-03 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna

Also Published As

Publication number Publication date
JPH10508181A (ja) 1998-08-18
ATE184649T1 (de) 1999-10-15
US5728521A (en) 1998-03-17
AU696138B2 (en) 1998-09-03
EP0748383B1 (de) 1999-09-15
US5869248A (en) 1999-02-09
EP0748383A1 (de) 1996-12-18
AU2116595A (en) 1995-09-25
CA2185117A1 (en) 1995-09-14
DE69512219T2 (de) 2000-01-20
WO1995024489A1 (en) 1995-09-14

Similar Documents

Publication Publication Date Title
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
EP0638121A1 (de) Gezielte spaltung von rna mittels eukaryontischer rnase p und externe führungssequenz.
Tang et al. Structural diversity of self-cleaving ribozymes
AR245776A1 (es) Metodo para la modificacion de las caracteristicas de expresion de un gen endogeno de un microorganismo o una linea celular determinada.
ATE267866T1 (de) Kurze externe führungssequenzen
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
ATE286118T1 (de) Anwendungen für humane nicht autologe, mesenchymale stammzellen
BR0014516A (pt) Composições e métodos de uso de delta-endotoxina do bacilo thuringiensis ativo de lepidopteran
SI1546174T1 (sl) Metode in sestavki za rna interferenco
DK1017803T3 (da) Ekspression af endogene gener ved ikke-homolog rekombination af et vektorkonstrukt med cellulært DNA
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
WO1999063101A3 (en) Transfected cells and methods for treating diabetes
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
DK0843731T3 (da) Adenovirusvektorer til genterapi
WO2000004918A3 (de) Mittel zur immuntherapie von tumorerkrankungen
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
AU7620501A (en) Methylated nucleotide regulation of gene expression
CO4790179A1 (es) Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena
MXPA02002444A (es) Metodo para generar celulas y tejidos inmunocompatibles, utilizando tecnicas de transferencia nuclear.
DE69233339D1 (de) Expressionsteigerung durch Gentargeting in endogene Retrovirus-ähnliche Sequenzen
HK1055444A1 (en) Mutant muscle-specific enhancers
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee